Irritable Bowel Syndrome With Diarrhea Clinical Trial
Official title:
Interest of Pan Capsule (Small Bowel and Colon Video Capsule) in Symptomatic Patients Suspected of Irritable Bowel Syndrome Requiring Colonoscopy. Phase A. Feasibility
Irritable bowel syndrome (IBS) is a chronic disease characterized by the association of
abdominal pain and transit disorders. IBS affects 5 to 10% of the population. There are
several forms of IBS: IBS-D (with predominant diarrhea), IBS-C (with constipation
predominant) and IBS-M (mixed with alternating diarrhea and constipation). In the absence of
a diagnostic test to confirm the existence of this syndrome, the diagnosis of IBS is based on
clinical criteria (Rome IV criteria). In patients suspected of IBS, especially in patients
with diarrhea (IBS-D or IBS-M), a colonoscopy with biopsies is often proposed in addition to
biological tests (Complete Blood Count, C-reactive protein, thyroid stimulating hormon and
anti-transglutaminase antibodies) by the physician or gastroenterologist to exclude an
organic digestive disease such as celiac disease, IBD (Crohn's disease or ulcerative
colitis), microscopic colitis or even neoplasia.
The colonoscopy is an invasive exploration and does not allow exploration of the entire small
bowel.
The development of capsules allowed the exploration of the small bowel more recently of the
colon. The new developed pan-capsule allows evaluation of both small bowel and colon.
The aim of this work is to evaluate in patients younger than 50 years, presenting suspicious
digestive symptoms of IBS with diarrhea, the interest of a strategy based on the pan-capsule
as an alternative to colonoscopy to eliminate a diagnosis of organic digestive disease
(celiac disease, IBD, neoplasia, ..).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00552565 -
Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
|
Phase 3 | |
| Completed |
NCT04950296 -
To Study the Efficacy and Safety of L. Plantarum UALp-05TM in Diarrhea- Predominant-irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT02959983 -
Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use
|
Phase 4 | |
| Withdrawn |
NCT02320318 -
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
|
Phase 3 | |
| Completed |
NCT01303224 -
Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
|
Phase 2 | |
| Recruiting |
NCT05646186 -
Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT04129619 -
A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
|
Phase 2 | |
| Recruiting |
NCT04855799 -
GI Permeability Change in Response to Aquamin®
|
Phase 2 | |
| Completed |
NCT04662957 -
Multi Strain Probiotic Preparation in Patients With Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT04557215 -
Efficacy and Safety of Rifaximin With NAC in IBS-D
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05311293 -
Study on the Molecular Mechanism of Diarrhea-predominant Irritable Bowel Syndrome With Anxiety and Depression Based on Multi-omics Correlation Analysis
|
||
| Completed |
NCT05277428 -
Clinical Study to Evaluate the IBS Symptoms Improving Effect and Safety of GTB1
|
N/A | |
| Not yet recruiting |
NCT03221790 -
Effect of FODMAPs on Mucosal Inflammation in IBS Patients
|
N/A | |
| Completed |
NCT03557788 -
Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome
|
Phase 4 | |
| Completed |
NCT02757105 -
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
|
Phase 2 | |
| Enrolling by invitation |
NCT06432569 -
Evaluation of Butyrate and Palmitoylethanolamide in IBS Patients (B/P3_1)
|
N/A | |
| Recruiting |
NCT04830410 -
The Effects of Carbohydrates in Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT03245645 -
FODMAP Reintroduction in Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT02107196 -
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
|
Phase 3 | |
| Terminated |
NCT02120027 -
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
|
Phase 3 |